Trial reportEuropean journal of nuclear medicine and molecular imaging2020
Prediction of lithium treatment response in bipolar depression using 5-HTT and 5-HT
Trial report in European journal of nuclear medicine and molecular imaging, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01880957 (Pathophysiology and Treatment of Bipolar Disorder as Assessed by in Vivo Imaging), which is not on this map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pathophysiology and Treatment of Bipolar Disorder as Assessed by in Vivo Imaging
Who cites it
9 citing papers in PubMed, 15 citations in OpenAlex.
- Serotonin 1A Receptor Binding of [11C]CUMI-101 in Bipolar Depression Quantified Using Positron Emission Tomography: Relationship to Psychopathology and Antidepressant Response.The international journal of neuropsychopharmacology · 2022Trial
- Habenular structural-functional dysconnectivity in bipolar disorder: evidence from multimodal imaging and transcriptomic integration.BMC psychiatry · 2026Article
- Genistein Exerts Neuroprotective Effects in an Ouabain-Induced Model of Bipolar Disorder: Behavioral and Molecular Insights.Neurochemical research · 2025Article
- The Mechanisms of Lithium Action: The Old and New Findings.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Transcriptional Regulation of the Human 5-HT1A Receptor Gene by Lithium: Role of Deaf1 and GSK3β.International journal of molecular sciences · 2023Article
- Article
- Gut Microbiota - A Potential Contributor in the Pathogenesis of Bipolar Disorder.Frontiers in neuroscience · 2022Review
- Rewiring of the Serotonin System in Major Depression.Frontiers in psychiatry · 2021Review
- Examining the underpinnings of loudness dependence of auditory evoked potentials with positron emission tomography.NeuroImage · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundLithium, one of the few effective treatments for bipolar depression (BPD), has been hypothesized to work by enhancing serotonergic transmission. Despite preclinical evidence, it is unknown whether lithium acts via the serotonergic system. Here we examined the potential of serotonin transporter (5-HTT) or serotonin 1A receptor (5-HT
resultsWe found lower pre-treatment 5-HTT binding (p = 0.003) and lower 5-HT
conclusionsOur findings suggest that while lithium may not act directly via 5-HTT or 5-HT CLINICAL
trial registrationPET and MRI Brain Imaging of Bipolar Disorder Identifier: NCT01880957; URL: https://clinicaltrials.gov/ct2/show/NCT01880957.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.